Cheap on paper at around 12–14× P/E vs. ~21× for the sector, and trading below estimated DCF/peer fair value. The company has a strong brand and solid growth potential, but it also carries meaningful risks, including thin margins, high customer/vendor concentration, a single production site, and negative FY25 operating cash flow. Overall, it may be worth considering with a modest position size rather than going all-in, provided you're comfortable with these risks. Strategy: - Apply for 2,000 shares on the public subscription day. The chances of full allocation appear relatively high. - Build the position gradually and maintain a minimum 1-year investment horizon. - If the business delivers strong growth and the valuation becomes stretched, consider partial profit-taking. - For a long-term wealth-building approach, consider holding and accumulating for at least 3 years, provided the fundamentals remain intact. All the best! Invest Wisely with Farhan Qaxi @Ammar Yaseen

I would classify STL as a potential growth/restructuring opportunity, but not yet a clean low-risk investment option. The bullish case is: Supernet operating business + merger synergies + new working capital + technology/ICT growth → higher future earnings. The risk case is: Major dilution + acquisition payment + limited cash cushion + unclear incremental project returns + PSX Risk Warning Alert. So for me, the key investment question is not: “Is Supernet profitable?” It is: “After increasing the share count by roughly 85%, can Supernet grow earnings and cash flow fast enough that earnings per share and shareholder value still increase?” #FarhanQaxi #InvestWisely #Investments #Analysis

A big thank you to @Ammar Yaseen & @Syed faraz for the mentorship, guidance, and practical insights throughout this trading journey. Putting the learning into practice delivered encouraging results: 5-Day Performance last week. - Total Return: +37.4% - Best Pair: XAU/USD (Gold) — 92.3% win rate - Key Learning: Following Gold trends with disciplined scaling-in - The biggest takeaway goes beyond the return: a structured strategy, disciplined execution, risk management, and the right mentorship can make a real difference. Still learning, refining, and improving. Thank you, @Sarmaaya Financials team Sarmaaya.pk Community, for sharing your experience and helping turn concepts into practical execution. Laeeq Ahmad

Fauji Cement + Attock Cement = bigger market coverage and stronger scale. Fauji Cement is stronger in the *North/Central region, while Attock Cement gives access to the **South, especially Karachi/Sindh*. So the potential benefits are: * wider market coverage * lower transport/logistics cost * better use of plants and distribution * stronger purchasing power * higher combined sales and profits * stronger competitive position Simple example: Instead of Fauji Cement transporting cement from the North to Karachi, Attock Cement’s southern presence can serve that market more efficiently. For investors, the key question is: Will the extra profit from Attock Cement be greater than the cost Fauji Cement pays for the acquisition? If yes, it can create value for FCCL shareholders. If not, it may put pressure on returns.

Imagine waking up to the headline: "Getz Pharma Announces IPO." Would it become one of the biggest and most sought-after listings on the Pakistan Stock Exchange? Today, investors looking for exposure to Pakistan's pharmaceutical sector can invest in listed companies such as GlaxoSmithKline Pakistan (GLAXO), Haleon Pakistan (HALEON), AGP Limited (AGP), Highnoon Laboratories (HINOON), Abbott Pakistan (ABOT), The Searle Company (SEARL), Ferozsons Laboratories (FEROZ), Hoechst Pakistan (HPL), BF Biosciences (BFBIO), and Citi Pharma (CPHL). Yet one of the industry's largest names remains unavailable to public investors. Why is Getz Pharma still private? Getz Pharma is wholly owned by Development Holdings Asia Limited (DHAL), with ownership ultimately controlled through the Getz Group's private holding structure rather than public shareholders. (Pakistan Stock Exchange) Possible reasons for remaining private include: - Preserving family ownership and strategic control. - No immediate need to raise capital from public markets. - Freedom to pursue long-term investments without quarterly earnings pressure. - Greater confidentiality around financial performance and business strategy. - Strong internal cash generation to fund expansion. The interesting part... According to IQVIA MAT March 2026 market data, Getz Pharma is the largest pharmaceutical company in Pakistan by sales, ahead of Abbott, Sami, GSK, Martin Dow, Hilton, Haleon, Searle, Highnoon, AGP, Atco and others. (Pakistan Stock Exchange) That's remarkable considering investors cannot own a single share of the company. What could an IPO unlock? - Access to capital for international expansion and acquisitions. - Increased transparency and corporate governance. - A new blue-chip healthcare investment for PSX. - Greater institutional and foreign investor participation. - A broader and deeper pharmaceutical sector on the exchange. - For long-term investors, it could become one of the most anticipated IPOs in Pakistan.